A double blind, randomised, placebo controlled, parallel group study o
A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis.
What was tested
Treatment tested
- Nabiximols
What it measured
Main measures
The primary endpoint is the mean pain due to MS NRS score taken from the daily IVRS diaries over the last seven days at the end of treatment during the evaluable period (usually week 14).
Pain
Loading reviews and guidelines…
Related trials
- Cryoneurolysis to treat pain in the context of spasticity
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spas
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pa
Phase 2 · Recruiting
Still running
- Antibiotic strategy and asymptomatic bacteriuria in the context of int
Phase 3 · Ongoing
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
History
- In scope changed from true to false
Started
Feb 2006
Assembled by software from public sources.